The liver is at the center of everything we do
Discovering and developing life-saving treatments for
patients with advanced liver disease
Our Story
Treatment and prevention
One critical path: Inflammation
Four targets
Five potential treatments
Our Pipeline
Poised to deliver clinical and commercial success
Team
14th May 2025
Yaqrit strengthens funding and regulatory capability ahead of clinical trials with board and senior management team appointments
7th May 2025
Yaqrit’s HE candidates set for phase 3 as company shows underpinning data at EASL
7th May 2025
EASL 2025 YAQ005 + YAQ007: Transcriptomic and metabolic insights into hyperammonemia
7th May 2025
EASL 2025 YAQ005: Toll-like receptor 4 inhibition restores cytochrome C oxidase
7th May 2025
EASL 2025: YAQ007 Randomized, open-label, phase 2a comparator study
